These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
618 related articles for article (PubMed ID: 12669467)
1. Development of prophylactic AIDS vaccines: the current state of affairs. Hanke T Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467 [TBL] [Abstract][Full Text] [Related]
2. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
3. [Development of HIV vaccines]. Shibata R Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790 [TBL] [Abstract][Full Text] [Related]
5. No vaccine against HIV yet--are we not perfectly equipped? Singh M Virol J; 2006 Aug; 3():60. PubMed ID: 16939652 [TBL] [Abstract][Full Text] [Related]
6. DNA vaccines against human immunodeficiency virus type 1. Estcourt MJ; McMichael AJ; Hanke T Immunol Rev; 2004 Jun; 199():144-55. PubMed ID: 15233732 [TBL] [Abstract][Full Text] [Related]
7. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Emini EA; Koff WC Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131 [No Abstract] [Full Text] [Related]
8. Clinical trials of HIV vaccines. Graham BS Annu Rev Med; 2002; 53():207-21. PubMed ID: 11818471 [TBL] [Abstract][Full Text] [Related]
9. Progress toward an HIV vaccine. Letvin NL Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510 [TBL] [Abstract][Full Text] [Related]
10. Anti-HIV adaptive immunity: determinants for viral persistence. Yamamoto H; Matano T Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450 [TBL] [Abstract][Full Text] [Related]
11. [Development of an AIDS vaccine: status report]. Girard MP Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791 [TBL] [Abstract][Full Text] [Related]
12. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518 [TBL] [Abstract][Full Text] [Related]
14. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression? Sheppard N; Sattentau Q Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051 [TBL] [Abstract][Full Text] [Related]
15. T lymphocyte responses in HIV-1 infection: implications for vaccine development. Brander C; Walker BD Curr Opin Immunol; 1999 Aug; 11(4):451-9. PubMed ID: 10448136 [TBL] [Abstract][Full Text] [Related]
16. AIDS vaccine development: the long and winding road. Garber DA; Feinberg MB AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562 [TBL] [Abstract][Full Text] [Related]
17. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-cell recognition of HIV proteins and peptides. Nixon DF; McMichael AJ AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319 [No Abstract] [Full Text] [Related]
19. Rates of HIV immune escape and reversion: implications for vaccination. Davenport MP; Loh L; Petravic J; Kent SJ Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018 [TBL] [Abstract][Full Text] [Related]
20. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. Yang OO AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558 [No Abstract] [Full Text] [Related] [Next] [New Search]